2. Disease Areas
  3. Inflammation or Immune System Disease
  4. Autoimmune Disease
  5. Myasthenia gravis

Myasthenia gravis

Myasthenia gravis is a rare, chronic autoimmune disorder characterized by fluctuating muscle weakness and fatigue due to impaired communication between nerves and muscles at the neuromuscular junction. It primarily affects voluntary muscles, including those controlling eye movements, facial expressions, swallowing, and limb movements, with symptoms typically worsening throughout the day and with activity. The condition results from autoantibodies targeting acetylcholine receptors, disrupting neuromuscular transmission. While it most commonly presents with ocular symptoms, it can involve multiple muscle groups, including the face, neck, arms, and legs. Myasthenia gravis can occur at any age, with a higher prevalence in women under 40 and men over 60, and may be associated with thymic abnormalities such as thymoma. Triggers like stress, infections, or certain medications can exacerbate symptoms, potentially leading to a life-threatening myasthenic crisis requiring respiratory support.

Myasthenia gravis (3):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-147305
    Efgartigimod alfa 1821402-21-4 99.47%
    Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research.
    Efgartigimod alfa
  • HY-P991127
    Claseprubart 2922766-89-8 99%
    Claseprubart (DNTH103) is an inhibitor targeting C1s of the complement system and an inhibitor of the C1 component of the complement cascade. Claseprubart is in phase 2 clinical evaluation. Claseprubart has application potential in research related to multifocal motor neuropathy and generalized myasthenia gravis.
    Claseprubart
  • HY-10540
    Sotrastaurin acetate 908351-31-5
    Sotrastaurin (AEB071) acetate is a selective, orally active PKC inhibitor. Sotrastaurin acetate inactivates NF-κB by inhibiting PKC α, β, θ, γ subtypes, thereby reducing the transcription levels of immune response-related genes. Sotrastaurin acetate effectively inhibits alloreactive T cell proliferation, conventional T cell activation, as well as the production of pro-inflammatory cytokines and B lymphocytes. Sotrastaurin acetate also maintains the functional and phenotypic stability of regulatory T cells, enhances Foxp3 expression and restores the balance of helper T lymphocytes. Sotrastaurin acetate can prolong the survival time of allografts, and alleviate inflammatory responses and myasthenic symptoms by reducing anti-AChR antibody levels. Sotrastaurin acetate is widely used in studies related to kidney transplantation, psoriasis and myasthenia gravis.
    Sotrastaurin acetate